Looking to empower your organizations with high quality patient data? Human abstraction has long been considered the gold standard for extracting high quality information from EHR data. With the rise of NLP, large language models, and machine learning, the question becomes: how should we evaluate these new technologies against the traditional abstraction methods?

Join Karim Galil and Sailu Challapalli as they walk through a breakthrough quality framework for understanding AI output.

In this webinar, we’ll cover:

  • Challenges facing Real-World Evidence Organizations
  • When should your organization use AI
  • A Quality Framework to assess how AI performs
  • How AI and Clinicians can work together
  • Q&A

Click here to find additional details and registration information.

Related Content

Synthesise RWE and AI. Transform patient-driven healthcare

Synthesise RWE and AI. Transform patient-driven healthcare

As the volume of the real word evidence data increases, the mechanisms to collect and translate the data into meaningful insights for pharmaceutical organisations becomes increasingly complex. Advances in technologies such as artificial technology have delivered global excitement, but mastering how to leverage AI for meaningful patient outcomes remains uncracked.
Transforming clinical research: Scaling real-world data across diseases with expert-led AI

Transforming clinical research: Scaling real-world data across diseases with expert-led AI

The promise of improving patient care and outcomes through RWD has been understood for some time, but overcoming the fragmentation and inaccessibility of disparate data sources across disease states has proven to be a hard challenge across the industry. We’re not learning fast enough— this is where clinical expert-led AI can help. By using AI to standardize unprecedented volumes of data, uncover clinical details that have previously been hidden in free text notes, and represent full patient journeys in near real-time, researchers can ask and answer complex questions for targeted populations like never before.